Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2014

View Archived Issues

Lilly to initiate clinical study of cancer candidate LY-3164530

Asterias Biotherapeutics receives FDA clearance to begin phase I/IIa trial of AST-OPC1

Genentech acquires Seragon Pharmaceuticals and gains selective estrogen receptor degraders

Oprozomib receives FDA orphan drug designation for Waldenstrom's macroglobulinemia

FDA grants orphan drug designation to recombinant human pentraxin-2

Identification of a lncRNA biomarker for colorectal cancer prognosis

Generation of novel minimal saponin immunoadjuvant with improved profile

Robust non-human primate model of MERS-CoV

Host cell CDK9 prevents the replication of DNA viruses

Fujifilm begins phase I trial of FF-10501 in relapsed or refractory myelodysplastic syndromes

Isis begins phase III study of ISIS-APOCIII Rx in familial chylomicronemia syndrome

Discovery of novel antibacterial agents with improved in vivo clearance

Allergan divulges new S1P1 receptor agonists

Biotie regains global rights to tozadenant

Immunotech Laboratories completes early clinical testing of antiviral immunomodulator ITV-1

Scientists in China disclose novel xanthine oxidase inhibitors

Merck & Co. describes new NS5B inhibitors for HCV infection

FDA grants fast track status to Pfizer's Clostridium difficile vaccine

Amgen submits evolocumab BLA, reports Japanese phase III results

Cavion formed from merger of Tau Therapeutics and Xdynia

OncoPep completes financing round to support development of MM vaccine

Dezima reports findings from phase IIb study of TA-8995 for dyslipidemia

AstraZeneca's MEDI-4736 to be studied in immunological subsets of advanced colorectal cancer

Nuplazid selected as trade name for pimavanserin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...